Irun Cohen, cofounder of Alma, conducted decades of research geared to increasing the understanding of autoimmune diseases. Those discoveries laid a foundation for developing therapies to curtail damaging autoimmunity without suppressing the immune system.
The team at Alma Biotherapeutic is striving to improve the current treatment of inflammatory bowel disease or IBD and other autoimmune diseases. Activating the immune system to better regulate itself would mark an improvement over the way autoimmune diseases are currently treated.
Alma Biotherapeutics is advancing a therapy to treat IBD. The therapy is designed to selectively halt the immune system’s attack on the intestine (Crohn’s Disease) by using its own signals. These signals are called Heat Shock Proteins (HSP).
Autoimmune Diseases are among the leading public health problems of the 21st century. There are more than 100 Million patients worldwide, including over 20 Million in Europe.
There are than 90 different types of autoimmune diseases. Notably juvenile diabetes, rheumatoid arthritis, IBD, multiple sclerosis, and psoriasis are among the diseases caused when the immune system turns on the body’s own tissues.
The incidence of autoimmune diseases is on the rise and approaching epidemic proportions. According to the French Inflammatory Bowel Disease or IBD Association the incidence of IBD has risen by 60% over an 8 year period.
Revenues from therapies to treat autoimmune diseases currently exceed €60 billion annually
CEO and co Founder
A seasoned biopharmaceutical executive and serial entrepreneur, Dr, Baum has participated in the founding of over 30 start ups located in Europe, the US and Israel. To-date, six have had successful exits. Dr. Baum teamed up with Dr. Cohen’s in founding Alma Biotherapeutics in order to apply new knowledge of the mechanisms underlying autoimmune disease to the development of therapeutic interventions for these chronic conditions.
Inventor, Chief Scientific Advisor and co Founder
Decades of research conducted by Dr. Cohen are the foundation for Alma’s Biotherapeutics drug discovery and development platform. Dr. Cohen is a world leading research immunologist who has received the Robert Koch Prize and the AESKU Prize for his Life Contribution to Autoimmunity Research. Dr. Cohen remains a Professor Emeritus of Immunology, Weizmann Institute of Science.
Director of Preclinical Development and Regulatory Affairs
Dr. Ravel brings 30 years’ experience as executive who has ushered drugs from concept to to the clinic for bio-pharmaceutical companies including Servier, Genset/MerckSerono, and Diatos.
“Immunity is a balancing act. Our approach attempts to tilt the balance away from the harmful inflammation associated with autoimmune diseases and toward healing.” World Leading Research Immunologist, Irun Cohen, Professor Emeritus of Immunology